David Salisbury | Director Of Immunization
UK Department of Health

David Salisbury, Director Of Immunization, UK Department of Health

Professor David Salisbury was Director of Immunisation at the Department of Health, London, until 2014; he was responsible for the national immunisation programme.
Professor Salisbury trained as a paediatrician at Oxford and at the Hospital for Sick Children, Great Ormond Street, London. He is a Fellow of the Royal College of Physicians, Fellow of the Royal College of Paediatrics and Child Health, Fellow of the Faculty of Public Health, and Fellow of the Academy of Medical Sciences. He has an honorary Chair at Imperial College, London and is an Associate Fellow of the Centre on Global Health Security at the Royal Institute of International Affairs, Chatham House, London. He is Chair of the Board of the Jenner Vaccine Foundation and was inaugural President of the International Association of Immunisation Managers.
Professor Salisbury was made a Companion of the Order of the Bath in the Queen’s Birthday Honours, 2001, for his services to immunisation.
Professor Salisbury continues to work extensively with the World Health Organization on the Global Programme for Vaccines. He was the Chair of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010. He is Chair of the Global Commission for Certification of Poliomyelitis Eradication and Chair of the European Region Certification Commission for Poliomyelitis Eradication. He serves on advisory boards for four EC-funded vaccine research projects. He has also had extensive experience in Global Health Security having co-chaired a G7 working group on Pandemic Influenza.
Professor Salisbury has written around 100 publications on immunisation and paediatric topics.


April 14 Pre-congress Workshop Day @ 10:00


Market access & regulatory challenges in vaccinesThe market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. Learn how get optimal value for our vaccines and avoid the pit falls when launching a new vaccine.
  • What to do about Vaccine Hesitancy: When the “Facts” and the “Truth” are Discordant
  • Accurately capturing the full benefits of vaccines
  • HTA assessments around the world: What are the key attributes that drive decisions?
  • Regulatory and public health approaches to clinical trial design and interpretation
  • Value based contracting and managed entry agreements – Making sure uncertainties at launch do not hinder market access
  • Industry perspective: Navigating market authorization applications and life cycle management for new vaccines
  • The Gavi Alliance approach to increasing vaccine access in low-income countries; targeting “Healthy Markets” for vaccines in low-income countries
  • Group discussion and Q&A with audience
last published: 11/Apr/19 16:05 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071